John L. Hays
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John L. Hays has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Theodore M. Brasky
The Ohio State University College of Medicine
9 shared publications - Alison M. Newton
The Ohio State University College of Medicine
8 shared publications - Holli A. Loomans-Kropp
Affiliations Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States of America, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America
5 shared publications - Juhua Luo
University of Indiana 9 Department of Epidemiology and Biostatistics Bloomington, Indiana
5 shared publications - Karen L. Margolis
HealthPartners, St Paul, MN, United States
5 shared publications - Leah R. Jager
Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington (A.K.A., L.F.T., H.R.H., L.R.J., G.L.A.)
5 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
Supplementary Figure 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
Supplementary Figure 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
- 20 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (11) , 2115-2123
Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
Purpose: Colorectal cancer is the second leading cause of cancer-related mortality in the United States. Chemotherapies based on 5-fluorouracil (5-FU), when combined with targeted agents, remain the standard of care for patients with metastatic or locally advanced disease. New treatment strategies are needed for patients with metastatic colorectal cancer with microsatellite stable disease. Preclinical studies have shown that riluzole, an oral medicine for amyotrophic lateral sclerosis, inhibits glutamate release and synergizes with 5-fluorouracil to reduce cell viability in colorectal cancer cell lines. Patients and Methods: In this single-arm, phase I trial of riluzole in combination with mFOLFOX6/bevacizumab for patients with metastatic colorectal cancer, the riluzole dose started at 50 mg twice daily, escalating to 100 mg twice daily or de-escalating to 50 mg once daily. Patients received riluzole for 16 weeks in combination with mFOLFOX6/bevacizumab for eight cycles. Patients then either continued mFOLFOX6/bevacizumab or switched therapies. Results: Twelve of the 14 patients enrolled were evaluable. All patients had previously received FOLFOX, and five patients (41.7%) showed disease resistance to it. Two patients obtained partial responses, nine had stable disease, and one had progressive disease. The objective response rate was 16.7%, and the disease control rate was 91.7%. The median duration of response was 4.9 months (95% confidence interval, 1.6–9.8). Median progression-free survival and overall survival were 4.89 and 12.98 months, respectively. Conclusions: Our study showed that riluzole plus mFOLFOX6/bevacizumab is well tolerated in patients with metastatic colorectal cancer and may have clinical activity in patients whose disease is resistant to FOLFOX.
- 20 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (11) , 2115-2123
Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
Purpose: Colorectal cancer is the second leading cause of cancer-related mortality in the United States. Chemotherapies based on 5-fluorouracil (5-FU), when combined with targeted agents, remain the standard of care for patients with metastatic or locally advanced disease. New treatment strategies are needed for patients with metastatic colorectal cancer with microsatellite stable disease. Preclinical studies have shown that riluzole, an oral medicine for amyotrophic lateral sclerosis, inhibits glutamate release and synergizes with 5-fluorouracil to reduce cell viability in colorectal cancer cell lines. Patients and Methods: In this single-arm, phase I trial of riluzole in combination with mFOLFOX6/bevacizumab for patients with metastatic colorectal cancer, the riluzole dose started at 50 mg twice daily, escalating to 100 mg twice daily or de-escalating to 50 mg once daily. Patients received riluzole for 16 weeks in combination with mFOLFOX6/bevacizumab for eight cycles. Patients then either continued mFOLFOX6/bevacizumab or switched therapies. Results: Twelve of the 14 patients enrolled were evaluable. All patients had previously received FOLFOX, and five patients (41.7%) showed disease resistance to it. Two patients obtained partial responses, nine had stable disease, and one had progressive disease. The objective response rate was 16.7%, and the disease control rate was 91.7%. The median duration of response was 4.9 months (95% confidence interval, 1.6–9.8). Median progression-free survival and overall survival were 4.89 and 12.98 months, respectively. Conclusions: Our study showed that riluzole plus mFOLFOX6/bevacizumab is well tolerated in patients with metastatic colorectal cancer and may have clinical activity in patients whose disease is resistant to FOLFOX.
- 7 February 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (4) , 101693
Assessment of readability of gynecologic cancer clinical trials literature at National Cancer Institute–designated Comprehensive Cancer Centers
- 7 February 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (4) , 101693
Assessment of readability of gynecologic cancer clinical trials literature at National Cancer Institute–designated Comprehensive Cancer Centers
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
Supplemental Table 1, shows associations of NSAIDs/aspirin with pancreatic cancer risk by categories of smoking, alcohol, and body mass index.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
Supplemental Table 1, shows associations of NSAIDs/aspirin with pancreatic cancer risk by categories of smoking, alcohol, and body mass index.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
Background:Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence.Methods:We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk.Results:Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03).Conclusions:Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes.Impact:This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
Background:Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence.Methods:We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk.Results:Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03).Conclusions:Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes.Impact:This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
Background:Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence.Methods:We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk.Results:Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03).Conclusions:Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes.Impact:This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
Background:Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence.Methods:We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk.Results:Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03).Conclusions:Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes.Impact:This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
Supplemental Table 1, shows associations of NSAIDs/aspirin with pancreatic cancer risk by categories of smoking, alcohol, and body mass index.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
Supplemental Table 1, shows associations of NSAIDs/aspirin with pancreatic cancer risk by categories of smoking, alcohol, and body mass index.
- 20 June 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 33 (9) , 1203-1210
Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
Background: Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence. Methods: We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk. Results: Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03). Conclusions: Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes. Impact: This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.
- 20 June 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 33 (9) , 1203-1210
Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
Background: Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence. Methods: We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk. Results: Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03). Conclusions: Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes. Impact: This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.